Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
NEW BRUNSWICK, N.J., February 11, 2020 – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services. The collaborative partnership with BARDA builds on Johnson & Johnson’s multipronged response to the new coronavirus disease (COVID-19) outbreak. In addition to Janssen’s ef...
Source: Johnson and Johnson - February 11, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
NEW BRUNSWICK, N.J., January 29, 2020 – Johnson & Johnson today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.“J&J has a long-standing comm...
Source: Johnson and Johnson - January 29, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

What Causes Respiratory Failure?
Discussion The respiratory system is a complex system. The upper airways must remain patient. The lower airways must interface with the vascular system. The musculoskeletal system must provide mechanical function and the central nervous system must provide overall control. Respiratory failure occurs when the overall system cannot support the body’s necessarily ventilation, oxygenation or both. Children are at higher risk of respiratory failure. They have few intrinsic lung parenchyma problems, but have very small airways that increase the airflow resistance by themselves but then have to contend with problems such as...
Source: PediatricEducation.org - December 2, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Childhood radiotherapy, chemo boost breast cancer risk
The combination of radiotherapy and chemotherapy treatment with anthracyclines...Read more on AuntMinnie.comRelated Reading: Echo screening cost-effective after childhood chemo Adult survivors of pediatric cancer risk pulmonary hypertension ASCO: Childhood radiation therapy boosts breast cancer risk Chemo lowers cancer risk for pediatric Hodgkin's survivors Childhood radiation exposure may increase risk of leukemia (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 28, 2019 Category: Radiology Source Type: news

Startup of the Week: Meet OxiWear
Shavini Fernando has a congenital heart defect. As a result, the 37-year-old entrepreneur suffers from severe pulmonary hypertension — which, on multiple occasions, has caused dangerously low oxygen levels. She didn’t know when it was happening until it was too late, and there wasn’t a tool that would tell her. So Fernando created one. N ow, she’s working full-time as part of Halcyon incubator’s current cohort to bring her product, OxiWear, to market. Millions of people suffer today from… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 25, 2019 Category: Biotechnology Authors: Sara Gilgore Source Type: news

Study identifies therapeutic target for high blood pressure in the lungs
This study was supported by grants from the National Institutes of Health and the American Heart Association; and by the Foundation for Anesthesia Education and Research. (Source: UCLA Newsroom: Health Sciences)
Source: UCLA Newsroom: Health Sciences - October 1, 2019 Category: Universities & Medical Training Source Type: news

United Therapeutics advances new pulmonary hypertension treatment to FDA review
United Therapeutics Corp. is a step closer to getting a new pulmonary arterial hypertension treatment to patients. The Silver Spring biotech’s New Drug Application for Trevyent, a treatment that uses treprostinil — the same active ingredient in three of United Therapeutics’ existing products — has been accepted by the Food and Drug Administration, the company announced Wednesday. The FDA will now revi ew the product, a combination of that drug and the technology to inject it subcutaneously,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 11, 2019 Category: Biotechnology Authors: Sara Gilgore Source Type: news

FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies
[12-14-2011] The U.S. Food and Drug Administration (FDA) is updating the public on the use of selective serotonin reuptake inhibitor (SSRI) antidepressants by women during pregnancy and the potential risk of a rare heart and lung condition known as persistent pulmonary hypertension of the newborn (PPHN). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension
The U.S. Food and Drug Administration (FDA) is recommending that Revatio (sildenafil) not be prescribed to children (ages 1 through 17) for pulmonary arterial hypertension (PAH; high pressure in the blood vessels leading to the lungs). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study Begins to Develop Breath Test for Mesothelioma Early Detection
This study has terrific significance and could be extremely important,” Harbut, clinical professor of internal medicine at Wayne State University and Michigan State University, told The Mesothelioma Center at Asbestos.com. “We’re going after this one with great guns.” The study is part of a new partnership between Owlstone Medical — the Breath Biopsy inventor in the United Kingdom — and the International Association of Heat and Frost Insulators and Allied Workers, a building trade union that covers the United States and Canada. Early Diagnosis Still a Rarity The first part of the study ...
Source: Asbestos and Mesothelioma News - June 18, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax(R) (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Observational registry (at midway point) with retrospective data collection provides preliminary evaluation of premature versus term and near-term neonates with pulmonary hypertension receiving inhaled nitric oxide STAINES-UPON-THAMES, United Kingdom, M... Biopharmaceuticals Mallinckrodt, INOmax, nitric oxide, pulmonary hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 6, 2019 Category: Pharmaceuticals Source Type: news

New report shows nearly 20 innovative medicines in development for sickle cell disease
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, afflicting nearly 100,000 Americans. Patients with SCD have sickle-shaped red blood cells, which have trouble moving through the blood vessels and thus cause blockages or slow blood flow and oxygen to parts of the body. SCD is life-threatening, due to potential complications from blocked blood vessels, which can include stroke, difficulty breathing, pulmonary hypertension and other organ damage. (Source: The Catalyst)
Source: The Catalyst - April 2, 2019 Category: Pharmaceuticals Tags: Medicines in Development Research and Development Rare Diseases New Era of Medicine Source Type: news

Cancer Fears Have Triggered Blood Pressure Drug Recalls for Months. Now Patients Are ‘Leery’
Cynthia Brown had been taking the drug valsartan for about two years when she learned last August that it had been recalled over fears of potential carcinogen contamination. Brown, a writer and patient advocate living near Cincinnati, had been prescribed valsartan to control shortness of breath related to primary pulmonary hypertension, but suddenly she had a whole new concern: cancer. “I’ve always been very conscientious about my health. I never dreamed I’d be on all these medications, and I’m real funny about what I take,” Brown, 65, says. “Valsartan has made me leery of all medication...
Source: TIME: Health - January 29, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs healthytime Source Type: news

A Deep Dive Into Pulmonary Hypertension
(MedPage Today) -- Andrew Perry, MD, interviews Murali Chakinala, MD (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - January 21, 2019 Category: Urology & Nephrology Source Type: news

Doppler-defined pulmonary hypertension in sepsis and septic shock
The authors of this study state that the association of pulmonary hypertension (PH) in patients with sepsis is lesser understood. In patients with sepsis and septic shock, PH is common and is noted to be associated with higher short and long-term mortality. Further studies are needed to understand the mechanisms by which PH is associated with outcomes. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 17, 2019 Category: Consumer Health News Source Type: news

What Are Potential Complications of Large for Gestational Birthweight?
Discussion Infant size at birth is determined mainly by genetics, but also pregnancy and environmental factors. Large for gestational age (LGA) is defined as a mean weight> 2 standard deviations above the weight for gestational age or above the 90th percentile on growth charts (or ~4000 g on WHO growth charts). Macrosomia is a term used for a term infant who is> 4000g. Risk factors for LGA infants includes: Male infant Maternal Genetic disposition Hispanic ethnicity Diabetic Multiparity or grand parity Obesity History of previous LGA infant Prenatal ultrasound is very helpful for antenatal management. First tri...
Source: PediatricEducation.org - January 14, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Blood pressure science paper in a pharmacology journal RETRACTED after data manipulation discovered
(Natural News) A 2011 paper published in the British Journal of Pharmacology (BJP) has been retracted after it was found that data represented in the study was manipulated. The paper, entitled, “Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension,” documented a study that concluded that a specific protein (which regulates various... (Source: NaturalNews.com)
Source: NaturalNews.com - January 10, 2019 Category: Consumer Health News Source Type: news

Treprostinil Boosts Exercise Capacity in Severe Thromboembolic Pulmonary HTN Treprostinil Boosts Exercise Capacity in Severe Thromboembolic Pulmonary HTN
Subcutaneous treprostinil appears safe and improves exercise capacity in patients with severe non-operable chronic thromboembolic pulmonary hypertension (CTEPH), according to results from a phase 3 randomized controlled trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

FDA grants breakthrough status to joint Merck-Bayer AI program
Merck and Bayer have been granted FDA Breakthrough Device Designation for the collaborative Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Artificial Intelligence Pattern Recognition software. CTEPH can be difficult to diagnose because its symptoms are similar to asthma and chronic obstructive pulmonary disease symptoms. CTEPH affects five people per million annually worldwide. Computed tomography pulmonary angiography and a ventilation/perfusion scan can be used to determine if thromboembolic occlusion is causing pulmonary hypertension in patients. Get the full story on our sister site, Medical Design & Outsour...
Source: Mass Device - December 10, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Food & Drug Administration (FDA) Bayer Merck Source Type: news

Large Companies Eye Collaboration as Entry into AI
Edwards Lifesciences is delving deeper into the realm of artificial intelligence through a partnership with San Francisco-based Bay Labs. The goal of the collaboration, which has multiple initiatives is to improve the detection of heart disease. Some of the initiatives include, the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite; support for ongoing clinical studies at institutions; and the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform. Irvine, CA-based Edwardsâ€...
Source: MDDI - December 10, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Drug Maker Pays $360 Million to Settle Investigation Into Charity Kickbacks
Prosecutors accused Actelion Pharmaceuticals, which Johnson& Johnson acquired in 2017, of violating Medicare laws by funneling money through a patient-assistance charity. (Source: NYT Health)
Source: NYT Health - December 6, 2018 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Prices (Fares, Fees and Rates) Actelion Pharmaceuticals Ltd Johnson & United Therapeutics Corporation Medicare Bribery and Kickbacks Pulmonary Hypertension Justice Department Health Insurance and Managed Care Source Type: news

FDA grants special designation for Bayer AI software
Bayer announced in a release that the U.S. Food and Drug Administration granted a breakthrough device designation for an AI pattern recognition software that it is jointly developing with Merck. The software is designed for the treatment of chronic thromboembolic Pulmonary Hypertension (CTEPH), a rare form of pulmonary hypertension that is often difficult to diagnose because symptoms often mimic those of asthma or chronic obstructive pulmonary disease (COPD). Working together, Bayer and Merck have… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 4, 2018 Category: Health Management Authors: Mike Larson Source Type: news

FDA Grants Breakthrough Device Designation to Artificial Intelligence Software for CTEPH Pattern Recognition from Bayer and MSD
Bayer announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA). (Source: eHealth News EU)
Source: eHealth News EU - December 4, 2018 Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news

FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA). (Source: World Pharma News)
Source: World Pharma News - December 3, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
The software in development intends to support clinical decision-making of chronic thromboembolic pulmonary hypertension– a progressive and life-threatening condition (Source: Bayer Company News)
Source: Bayer Company News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Protein central to immune system function new target for treating pulmonary hypertension
(Virginia Commonwealth University) A protein with a role in sensing cell damage and viral infections is a new target for the treatment of pulmonary hypertension, or increased blood pressure in the lungs, according to research led by Virginia Commonwealth University and the University of Sheffield in the United Kingdom. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 15, 2018 Category: International Medicine & Public Health Source Type: news

Influence of Anemia on One-Year Exacerbation Rate of COPD-PH Influence of Anemia on One-Year Exacerbation Rate of COPD-PH
A new study explores the potential prognostic role of anemia in patients with pulmonary hypertension due to COPD.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

PADN-5: Ablation Reduces Pulmonary Hypertension in HF PADN-5: Ablation Reduces Pulmonary Hypertension in HF
Pulmonary artery denervation improved hemodynamic and clinical outcomes at 6 months, but design flaws in the sham-controlled study may muddy the results, a clinical trials expert cautions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 24, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments Research agreement for additional products for additional $10 million SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif., Sept. 4, 2018 -- (Hea... Biopharmaceuticals, Licensing United Therapeutics, MannKind, Treprostinil, Technosphere (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 4, 2018 Category: Pharmaceuticals Source Type: news

Deadly Respiratory Distress Mimic
Conclusion It’s important for prehospital providers to be able to differentiate metabolic disturbances in the setting of respiratory distress and not be fooled into thinking tachypnea always has a respiratory cause. The physical exam and adjuncts such as end-tidal capnography can assist in the prehospital diagnosis. A COPD exacerbation generally presents as diminished lung sounds, wheezing on exhalation, and a prolonged expiratory phase. Here, a patient will attempt to compensate for the inflammation and mucus accumulation associated with the destruction and narrowing of peripheral airways and a subsequent lack of av...
Source: JEMS Special Topics - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Exclusive Articles Patient Care Source Type: news

SPONSORED: Handy Help For The Heart
Knowledge of symptoms and available treatments are key to fighting atrial fibrillation and pulmonary hypertension. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - June 20, 2018 Category: American Health Source Type: news

New pulmonary hypertension treatment target in the bull's-eye
(Medical College of Georgia at Augusta University) A new and early target for treating pulmonary hypertension appears to be an enzyme that's normally key to energy production but destructive in the face of this high blood pressure inside your lungs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2018 Category: Biology Source Type: news

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT ® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 30, 2018 Category: Pharmaceuticals Source Type: news

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT(R) (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Filing supported by data from MERIT-1 trial evaluating OPSUMIT in adults with inoperable CTEPH which showed significant improvements in pulmonary vascular resistance and six-minute walk distance (6MWD) compared with ongoing background therapy CHERRY HIL... Biopharmaceuticals, FDA Actelion Pharmaceuticals, Janssen, Johnson & Johnson, OPSUMIT, macitentan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2018 Category: Pharmaceuticals Source Type: news

Study identifies new target for treatment of pulmonary hypertension
(Ann& Robert H. Lurie Children's Hospital of Chicago) Inhibiting FoxM1 gene reverses disease process in animal models of pulmonary hypertension. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2018 Category: International Medicine & Public Health Source Type: news

Crosstalk between cells plays role in pulmonary hypertension
Molecular signals between specialized cells in the lungs and arteries may be responsible for high blood pressure in the lungs, according to new research. (Source: Yale Science and Health News)
Source: Yale Science and Health News - April 24, 2018 Category: Universities & Medical Training Source Type: news

Pulmonary Hypertension: Not Just for Cardiologists
(MedPage Today) -- PH is common in many rheumatologic conditions (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 19, 2018 Category: Cardiology Source Type: news

Genes isolated for pulmonary arterial hypertension
Doctors hope the discovery will lead to potential new treatments Related items fromOnMedica Antidepressant link to persistent pulmonary hypertension NHS funds pioneering lung procedure Researchers identify gene for irregular heartbeat Scientists find new markers for high blood pressure UK mass gene sequencing breakthrough (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 16, 2018 Category: UK Health Source Type: news

Pregnancy Outcome in a Pregnant Patient With Idiopathic PAH Pregnancy Outcome in a Pregnant Patient With Idiopathic PAH
While the risk of mortality in pregnant patients with idiopathic pulmonary hypertension remains high, this case demonstrates that with proper care it is possible for these patients to carry to term.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Hemodynamic Parameters Predict Outcome in PH - HFpEF
Tied to mortality, hospitalization in pulmonary hypertension in HF with preserved ejection fraction (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 16, 2018 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Pulmonology, Journal, Source Type: news

HFpEF With Pulmonary Vascular Disease: A New Phenotype? HFpEF With Pulmonary Vascular Disease: A New Phenotype?
What do we know about the emerging clinical syndrome of pulmonary hypertension in HFpEF, and what do we still need to learn? This brief summarizes current knowledge of this newly recognized problem.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Boston Children ’ s, Boston Pediatric Device Consortium announces device challenge winners
The Boston Pediatric Device Strategic Partner Challenge recently announced its winners, including cardiovascular devices that expand to keep pace with growing child, a nitric oxide generator, a cardiovascular diagnostic device and other novel pediatric devices. The challenge, run by the Innovation and Digital Health Accelerator at Boston Children’s Hospital and the Boston Pediatric Device Consortium, announced a total of five winners for the challenge. Winners will receive a combination of up to $50,000 in funding per grant award and possible mentorship programs with medical device strategic partners, including Bosto...
Source: Mass Device - January 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Boston Children's Hospital Boston Scientific CryoLife Edwards Lifesciences johnsonandjohnson Medtronic Ximedica LLC Source Type: news

Doctors who order fewer CTPA scans detect more PE
Turns out that less really is more. Canadian researchers are reporting that...Read more on AuntMinnie.comRelated Reading: Ultrasound elevates diagnosis of pulmonary embolism ACP: Routine CT for suspected PE is unnecessary CTPA-based prediction model nails pulmonary hypertension ARRS: Pulmonary MRI feasible for evaluating acute PE CAD may catch missed pulmonary embolism on CTPA studies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 8, 2018 Category: Radiology Source Type: news

Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. Get the full story at out sister site, Drug Delivery Business News. The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Bellerophon Therapeutics Source Type: news

Pulmonary Hypertension Treatment and Research
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - December 12, 2017 Category: Consumer Health News Source Type: news

Genes on Y chromosome protect against pulmonary hypertension, study suggests
This study is the first to examine the involvement of sex chromosomes in the disease's development in the absence of sex hormones. In humans, females typically have two copies of the X chromosome, while males typically have one X and one Y chromosome.METHODIn the lab, the researchers engineered mice with different chromosomal makeups and measured their development of pulmonary hypertension in an environment with 10 percent oxygen, which is a well-established setting for inducing the disease.One group of mice was engineered with sex chromosomes that were independent of their gonadal sex, or sex based on their genitalia, so ...
Source: UCLA Newsroom: Health Sciences - December 4, 2017 Category: Universities & Medical Training Source Type: news

Critical Care Management of Pulmonary Hypertension Critical Care Management of Pulmonary Hypertension
How should patients with pulmonary hypertension in the critical care setting be approached? This overview highlights key points in diagnosis and management of this challenging disorder.BJA Education (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 28, 2017 Category: Intensive Care Tags: Critical Care Journal Article Source Type: news